CONTINUE TO SITE

OR WAIT null SECS

Cataract Surgical Case Study Cataract Therapeutics Glaucoma Insights CME Activities Dry Eye Viewpoint Diabetic Eye Disease Viewpoints Cornea Updates Diabetic Eye Disease Podcast DME Therapy Dry Eye Concepts Dry Eye Flares Eyevance Case Studies Management of Dry Eye Viewpoints Ptosis WetAMD Viewpoints

Clinical

View More Cataract Clinical Diagnosis Cornea Glaucoma IOL OCT Ocular Allergy Ocular Surface Disease Pediatrics Refractive Retina Technology Therapeutic Cataract & Refractive Understanding Antibiotic Resistance

Cataract Clinical Diagnosis Cornea Glaucoma IOL OCT Ocular Allergy Ocular Surface Disease Pediatrics Refractive Retina Technology Therapeutic Cataract & Refractive Understanding Antibiotic Resistance

All News Blogs COVID-19

Expert Interviews Medical World News Podcasts Viewpoints Insights Case Studies

Health Law & Policy Money Matters Personal Finance Practice Management

Conferences

Conference Coverage

Conference Listing

Conference Coverage Conference Listing

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Digital Edition Europe Ophthalmology Times Modern Retina Supplements and Featured Publications

Ocular bacterial treatment in development

September 15, 2002

Alameda, CA-InSite Vision Inc. and Bausch & Lomb have signed a licensing agree-ment to develop InSite's product ISV-403 for the treatment of ocular bacterial infections.

Related Content:

Personal Finance

Planning for financial safety in uncertain times

What can we learn from COVID-19?

What we've learned from the commonalities of financial aspirations, fears